Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 25;10(1):57.
doi: 10.1186/s40834-025-00368-1.

Mesenchymal stem cells and platelet rich plasma in the treatment of premature ovarian insufficiency: a scoping review

Jack Gemayel  1   2 , Frédéric Harb  3 , Farah Karam  3 , Donna Tahan  3 , Monique Younes  3 , Yvanna Saliba  3 , Diana Chaker  4   5 , Ahmad Ibrahim  3 , Albert Azar  4 , Mustapha Chaaban  3   6 , Alain Chebly  7   8 , Khalil Akouch  4 , Charbel Khalil  9   10   11
Affiliations
Review

Mesenchymal stem cells and platelet rich plasma in the treatment of premature ovarian insufficiency: a scoping review

Jack Gemayel et al. Contracept Reprod Med. .

Abstract

Premature ovarian Insufficiency (POI) is characterized by amenorrhea, hypergonadotropic hypogonadism, estrogen deficiency, and reduced follicle counts leading to infertility under the age of 40. It occurs in 1 to 3% of women. Several therapeutic strategies have been explored in clinic for POI. Platelet Rich Plasma (PRP) a blood product applied in regenerative medicine, which is based on the releasing of the growth factors present in platelet. Mesenchymal Stem Cells derived from Bone marrow, adipose tissue or cord blood tissue are undifferentiated cells with a potential for self-renewal and differentiation into multiple mature cell type. Mesenchymal stem cells secretome can stimulate cellular process and activate multipotent stem cells to generate new younger tissue and blood vessels relevant to ovarian rejuvenation and endometrial regeneration. This review provides a critical analysis on novel treatments that have not achieve routine clinical practice status yet but have recently emerged as promising potential therapy.

Keywords: Mesenchymal stem cells; Platelet rich plasma; Premature ovarian insufficiency; Secretome; Stem cell therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: All authors declare and approved the manuscript for publication. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Injection of MSC and Secretome and PRP in POI
See this image and copyright information in PMC

References

    1. Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017;16(2):51–6. - PMC - PubMed
    1. Huang Y, Zhu M, Liu Z, Hu R, Li F, Song Y et al. Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects. Front Immunol. 2022 Oct 27 [cited 2023 May 11];13. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.997808/full - PMC - PubMed
    1. Vujović S, Ivović M, Tancić-Gajić M, Marina L, Barać M, Arizanović Z, et al. Premature ovarian failure. Srp Arh Celok Lek. 2012;140(11–12):806–11. - DOI - PubMed
    1. Lv X, Guan C, Li Y, Su X, Zhang L, Wang X, et al. Effects of single and multiple transplantations of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice. J Ovarian Res. 2021;14(1):119. - DOI - PMC - PubMed
    1. Ebrahimi M, Akbari Asbagh F. Pathogenesis and causes of premature ovarian failure: an update. Int J Fertil Steril. 2011;5(2):54–65. - PMC - PubMed

LinkOut - more resources